

# Winette T A Van Der Graaf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1220558/publications.pdf>

Version: 2024-02-01

355  
papers

15,801  
citations

22548

61  
h-index

27587

110  
g-index

358  
all docs

358  
docs citations

358  
times ranked

18277  
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?. <i>European Journal of Surgical Oncology</i> , 2022, 48, 500-507.	0.5	7
2	Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. <i>Clinical Cancer Research</i> , 2022, 28, 1402-1411.	3.2	24
3	Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients. <i>Cancers</i> , 2022, 14, 436.	1.7	10
4	Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis. <i>Cancers</i> , 2022, 14, 709.	1.7	8
5	Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data. <i>Supportive Care in Cancer</i> , 2022, 30, 5137-5146.	1.0	3
6	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database. <i>Sarcoma</i> , 2022, 2022, 1-13.	0.7	1
7	Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. <i>Cancers</i> , 2022, 14, 1832.	1.7	15
8	Next Step for Global Adolescent and Young Adult Oncology: A Core Patient-Centered Outcome Set. <i>Journal of the National Cancer Institute</i> , 2022, 114, 496-502.	3.0	7
9	"I thought I had fibroids, and now I don't": a mixed method study on health-related quality of life in uterine sarcoma patients. <i>Health and Quality of Life Outcomes</i> , 2022, 20, 65.	1.0	2
10	First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Cancer</i> , 2022, 128, 2932-2938.	2.0	3
11	Psychosocial consequences of surviving cancer diagnosed and treated in childhood versus in adolescence/young adulthood: A call for clearer delineation between groups. <i>Cancer</i> , 2022, 128, 2690-2694.	2.0	0
12	Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes. <i>Cancers</i> , 2022, 14, 2979.	1.7	5
13	The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 326-335.	1.1	18
14	Diagnosed with a Rare Cancer: Experiences of Adult Sarcoma Survivors with the Healthcare System—Results from the SURVSARC Study. <i>Cancers</i> , 2021, 13, 679.	1.7	15
15	Clinical Trials for Real-World Elderly Patients With Metastatic Soft-Tissue Sarcomas: The Importance of Study Design and Patient-Reported Outcomes. <i>Journal of Clinical Oncology</i> , 2021, 39, 860-861.	0.8	1
16	Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The "New Lost Tribe". <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 240-246.	2.3	24
17	Health-Related Quality of Life Issues in Adolescents and Young Adults with Cancer: Discrepancies with the Perceptions of Health Care Professionals. <i>Journal of Clinical Medicine</i> , 2021, 10, 1833.	1.0	13
18	The patient perspective in the era of personalized medicine: What about scanxiety?. <i>Cancer Medicine</i> , 2021, 10, 2943-2945.	1.3	17

#	ARTICLE	IF	CITATIONS
19	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
20	Genomic and transcriptomic characterization of desmoplastic small round cell tumors. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 595-603.	1.5	6
21	Supportive care needs of patients living with an extremely rare and unpredictable cancer: The Epithelioid Haemangi endothelioma patient experience. <i>European Journal of Cancer Care</i> , 2021, 30, e13461.	0.7	1
22	Comprehensive Assessment of Incidence, Risk Factors, and Mechanisms of Impaired Medical and Psychosocial Health Outcomes among Adolescents and Young Adults with Cancer: Protocol of the Prospective Observational COMPRAYA Cohort Study. <i>Cancers</i> , 2021, 13, 2348.	1.7	5
23	Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?. <i>Journal of Clinical Oncology</i> , 2021, 39, e23539-e23539.	0.8	0
24	"This is not part of my life plan": A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39 years at diagnosis. <i>European Journal of Cancer Care</i> , 2021, 30, e13458.	0.7	10
25	The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study): A Protocol for an International Cohort Study. <i>Cancers</i> , 2021, 13, 3068.	1.7	9
26	The heterogeneity of Epithelioid Hemangi endothelioma (EHE): A case series and review of the literature with emphasis on treatment options. <i>Seminars in Oncology</i> , 2021, 48, 111-118.	0.8	10
27	PARP inhibition in UV-associated angiosarcoma preclinical models. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2579-2590.	1.2	2
28	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 154, 253-268.	1.3	8
29	Describing Unmet Supportive Care Needs among Young Adults with Cancer (25-39 Years) and the Relationship with Health-Related Quality of Life, Psychological Distress, and Illness Cognitions. <i>Journal of Clinical Medicine</i> , 2021, 10, 4449.	1.0	3
30	Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview. <i>Cancers</i> , 2021, 13, 4847.	1.7	66
31	Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?. <i>Biomedicines</i> , 2021, 9, 1315.	1.4	10
32	The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. <i>International Journal of Cancer</i> , 2021, 148, 2799-2806.	2.3	8
33	Psychological aspects in patients with advanced cancer receiving lifelong systemic treatment: protocol for a scoping review. <i>BMJ Open</i> , 2021, 11, e042404.	0.8	3
34	The Prolonged Diagnostic Pathway of Young Adults (Aged 25-39) with Cancer in the United Kingdom: Results from the Young Adult Cancer Patient Journey Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4646.	1.0	2
35	Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. <i>Cancers</i> , 2021, 13, 1.	1.7	189
36	Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent. <i>Nuclear Medicine - Nuclear Medicine</i> , 2021, 60, 411-416.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 5334.	1.0	2
38	Differences in Internet Use and eHealth Needs of Adolescent and Young Adult Versus Older Cancer Patients; Results from the PROFILES Registry. <i>Cancers</i> , 2021, 13, 6308.	1.7	5
39	DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas. <i>Clinical Cancer Research</i> , 2020, 26, 93-100.	3.2	34
40	The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry. <i>Oncologist</i> , 2020, 25, e722-e732.	1.9	107
41	EORTC SPECTRA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. <i>International Journal of Cancer</i> , 2020, 147, 1180-1184.	2.3	11
42	Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase II randomized phase II study Commence. <i>Head and Neck</i> , 2020, 42, 828-838.	0.9	12
43	Does a regular nurse-led distress screening and discussion improve quality of life of breast cancer patients treated with curative intent? A randomized controlled trial. <i>Psycho-Oncology</i> , 2020, 29, 719-728.	1.0	10
44	A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. <i>European Journal of Cancer</i> , 2020, 124, 77-87.	1.3	54
45	Imatinib, sunitinib and pazopanib: From flat dosing towards a pharmacokinetically guided personalized dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 258-273.	1.1	56
46	Patient and diagnostic intervals of survivors of sarcoma: Results from the SURVSARC study. <i>Cancer</i> , 2020, 126, 5283-5292.	2.0	19
47	Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15-39 Years): A Population-Based Study in The Netherlands 1990-2016. <i>Cancers</i> , 2020, 12, 3421.	1.7	43
48	Quality of life and experiences of sarcoma trajectories (the QUEST study): protocol for an international observational cohort study on diagnostic pathways of sarcoma patients. <i>BMJ Open</i> , 2020, 10, e039309.	0.8	2
49	The Perceived Impact of Length of the Diagnostic Pathway Is Associated with Health-Related Quality of Life of Sarcoma Survivors: Results from the Dutch Nationwide SURVSARC Study. <i>Cancers</i> , 2020, 12, 2088.	1.7	7
50	Unravelling the heterogeneity of soft tissue and bone sarcoma patients' health-related quality of life: a systematic literature review with focus on tumour location. <i>ESMO Open</i> , 2020, 5, e000914.	2.0	19
51	Unraveling the Heterogeneity of Sarcoma Survivors' Health-Related Quality of Life Regarding Primary Sarcoma Location: Results from the SURVSARC Study. <i>Cancers</i> , 2020, 12, 3083.	1.7	22
52	Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries. <i>Sarcoma</i> , 2020, 2020, 1-9.	0.7	7
53	PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study. <i>BMJ Open</i> , 2020, 10, e039449.	0.8	7
54	Neoadjuvant Systemic Treatment of Primary Angiosarcoma. <i>Cancers</i> , 2020, 12, 2251.	1.7	20

#	ARTICLE	IF	CITATIONS
55	The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes. <i>ESMO Open</i> , 2020, 5, e000592.	2.0	42
56	Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 628-638.	0.7	10
57	Health-related quality Of Life <b>I</b>n patients with advanced Soft Tissue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study. <i>BMJ Open</i> , 2020, 10, e035171.	0.8	8
58	Health-related quality of life and symptom burden of epithelioid hemangioendothelioma patients: a global patient-driven Facebook study in a very rare malignancy. <i>Acta OncolÃ³gica</i> , 2020, 59, 975-982.	0.8	9
59	The complexity of assessing health-related quality of life among sarcoma patients. <i>Quality of Life Research</i> , 2020, 29, 2613-2614.	1.5	8
60	Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT). <i>Trials</i> , 2020, 21, 86.	0.7	11
61	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	2.0	42
62	Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1659-1670.	1.2	13
63	Gastrointestinal Stromal Tumours (GIST) in Young Adult (18â€™40 Years) Patients: A Report from the Dutch GIST Registry. <i>Cancers</i> , 2020, 12, 730.	1.7	15
64	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	1.3	243
65	Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3613-3613.	0.8	2
66	The route to diagnosis of sarcoma patients: Results from an interview study in the Netherlands and the United Kingdom. <i>PLoS ONE</i> , 2020, 15, e0243439.	1.1	8
67	Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11556-11556.	0.8	0
68	Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or highâ€™dose cisplatinâ€™based chemoradiotherapy. <i>Head and Neck</i> , 2019, 41, 488-494.	0.9	6
69	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. <i>Oncologist</i> , 2019, 24, 110-116.	1.9	34
70	The effect of gastrectomy on regorafenib exposure and progressionâ€™free survival in patients with advanced gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2399-2404.	1.1	5
71	Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. <i>Annals of Surgical Oncology</i> , 2019, 26, 4699-4706.	0.7	36
72	The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. <i>Anticancer Research</i> , 2019, 39, 4891-4896.	0.5	13

#	ARTICLE	IF	CITATIONS
73	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<sc>DIET</sc> Study). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1076-1082.	2.3	26
74	Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients. <i>Sarcoma</i> , 2019, 2019, 1-11.	0.7	1
75	Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1994-2001.	1.1	24
76	Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE) Tj ETQq0 0 0 rgt /Overlock 10 TF		
77	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. <i>Anticancer Research</i> , 2019, 39, 1309-1316.	0.5	8
78	Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study. <i>European Journal of Cancer</i> , 2019, 113, 32-40.	1.3	12
79	Caregiversâ€™ burden and fatigue during and after patientsâ€™ treatment with concomitant chemoradiotherapy for locally advanced head and neck cancer: a prospective, observational pilot study. <i>Supportive Care in Cancer</i> , 2019, 27, 4145-4154.	1.0	20
80	Impact of Concomitant Administration of Gastric Acidâ€™Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1479-1485.	3.2	63
81	Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. <i>Anticancer Research</i> , 2019, 39, 347-351.	0.5	0
82	Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas. <i>Cancers</i> , 2019, 11, 1780.	1.7	22
83	Desmoid fibromatosis through the patientsâ€™ eyes: time to change the focus and organisation of care?. <i>Supportive Care in Cancer</i> , 2019, 27, 965-980.	1.0	28
84	Bone sarcoma during pregnancy: an example of personalized multidisciplinary care. <i>Acta Oncologica</i> , 2019, 58, 128-131.	0.8	0
85	A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. <i>Journal of Clinical Oncology</i> , 2019, 37, 4564-4564.	0.8	2
86	The effect of gastrectomy in regorafenib treated GIST patients on outcome and drug exposure.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22511-e22511.	0.8	0
87	Prevalence and correlates of high fear of cancer recurrence in late adolescents and young adults consulting a specialist adolescent and young adult (AYA) cancer service. <i>Supportive Care in Cancer</i> , 2018, 26, 1479-1487.	1.0	28
88	Young adults: a unique group in cancer epidemiological research. <i>Lancet Oncology</i> , The, 2018, 19, e72.	5.1	1
89	Systemic Treatment for Adults with Synovial Sarcoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 13.	1.3	67
90	A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from <sc>T</sc>he <sc>N</sc>etherlands. <i>International Journal of Cancer</i> , 2018, 143, 758-766.	2.3	81

#	ARTICLE	IF	CITATIONS
91	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. <i>Oncologist</i> , 2018, 23, 1250-1259.	1.9	25
92	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-ESTBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	2.3	32
93	Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. <i>Head and Neck</i> , 2018, 40, 605-613.	0.9	94
94	Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. <i>Acta Oncologica</i> , 2018, 57, 1117-1126.	0.8	11
95	Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. <i>Journal of Nuclear Medicine</i> , 2018, 59, 194-196.	2.8	24
96	Post-Traumatic Growth and Resilience in Adolescent and Young Adult Cancer Patients: An Overview. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018, 7, 1-14.	0.7	74
97	Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2018, 26, 1233-1242.	1.0	5
98	Health-Related Quality of Life in Patients With Sarcoma: Enhancing Personalized Medicine. <i>Journal of Clinical Oncology</i> , 2018, 36, 1642-1643.	0.8	9
99	Online support community for adolescents and young adults (AYAs) with cancer: user statistics, evaluation, and content analysis. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2615-2622.	0.8	36
100	Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. <i>Medical Oncology</i> , 2018, 35, 138.	1.2	26
101	Age-related sarcoma patient experience: results from a national survey in England. <i>BMC Cancer</i> , 2018, 18, 991.	1.1	28
102	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. <i>Sarcoma</i> , 2018, 2018, 1-8.	0.7	14
103	Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: Results from the PROFILES Registry. <i>Head and Neck</i> , 2018, 40, 2235-2245.	0.9	31
104	Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. <i>European Journal of Cancer</i> , 2018, 101, 55-61.	1.3	6
105	Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study. <i>Quality of Life Research</i> , 2018, 27, 3097-3111.	1.5	17
106	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. <i>Medical Oncology</i> , 2018, 35, 131.	1.2	14
107	Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies. <i>Blood</i> , 2018, 132, 385-392.	0.6	34
108	Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.. <i>Journal of Clinical Oncology</i> , 2018, 36, 92-92.	0.8	69

#	ARTICLE	IF	CITATIONS
109	A single digital droplet PCR assay to detect multiple <i>KIT</i> exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. <i>Oncotarget</i> , 2018, 9, 13870-13883.	0.8	28
110	Genetic variants as predictive markers for ototoxicity and nephrotoxicity in patients (pts) with locally advanced head and neck cancer (LAHNC) treated with cisplatin-containing chemoradiotherapy (ccCRT).. <i>Journal of Clinical Oncology</i> , 2018, 36, e18010-e18010.	0.8	0
111	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11540-11540.	0.8	1
112	TIREd: A randomised controlled trial evaluating efficacy of cognitive behavior therapy and graded exercise therapy in severely fatigue patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 183-183.	0.8	1
113	Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. <i>Lancet Oncology</i> , The, 2017, 18, e166-e175.	5.1	100
114	Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. <i>Acta OncolÃ³gica</i> , 2017, 56, 288-294.	0.8	51
115	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. <i>Acta OncolÃ³gica</i> , 2017, 56, 1013-1020.	0.8	29
116	Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2195-2204.	1.1	61
117	Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study. <i>Clinical Sarcoma Research</i> , 2017, 7, 2.	2.3	8
118	Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity â€œ A retrospective multicentre study in a large cohort of GIST patients. <i>European Journal of Cancer</i> , 2017, 86, 318-325.	1.3	23
119	The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. <i>European Journal of Cancer</i> , 2017, 84, 257-261.	1.3	10
120	Empowerment in adolescents and young adults with cancer: Relationship with healthâ€™related quality of life. <i>Cancer</i> , 2017, 123, 4039-4047.	2.0	44
121	Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers. <i>Annals of Surgical Oncology</i> , 2017, 24, 3279-3288.	0.7	41
122	Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2312-2314.	1.1	7
123	Fatal heart failure in a young adult female sarcoma patient treated with pazopanib. <i>Acta OncolÃ³gica</i> , 2017, 56, 1233-1234.	0.8	8
124	Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib. <i>Targeted Oncology</i> , 2017, 12, 815-826.	1.7	25
125	Prevalence and impact of severe fatigue in adolescent and young adult cancer patients in comparison with population-based controls. <i>Supportive Care in Cancer</i> , 2017, 25, 2911-2918.	1.0	32
126	Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. <i>Head and Neck</i> , 2017, 39, 140-146.	0.9	48



#	ARTICLE	IF	CITATIONS
127	Towards an evidence-based model of fear of cancer recurrence for breast cancer survivors. <i>Journal of Cancer Survivorship</i> , 2017, 11, 41-47.	1.5	35
128	Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. <i>Future Oncology</i> , 2017, 13, 93-107.	1.1	99
129	Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. <i>Future Oncology</i> , 2017, 13, 185-194.	1.1	8
130	Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 130.	1.5	12
131	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. <i>Journal of Clinical Oncology</i> , 2017, 35, 1713-1720.	0.8	148
132	Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here?. <i>Lancet Oncology</i> , The, 2017, 18, 706-707.	5.1	6
133	Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10536-10536.	0.8	1
134	Incidence and survival trends of cancers diagnosed in young adults (20-39 years): A population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1567-1567.	0.8	1
135	Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer. <i>Head and Neck</i> , 2016, 38, E1575-81.	0.9	19
136	The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 768-772.	1.1	5
137	Experiences of Parents and General Practitioners with End-of-Life Care in Adolescents and Young Adults with Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 64-68.	0.7	12
138	The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial. <i>BMC Cancer</i> , 2016, 16, 520.	1.1	10
139	Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 265-271.	0.6	24
140	Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?. <i>Acta Oncologica</i> , 2016, 55, 444-448.	0.8	6
141	Time to practice what we preach? Appreciating the autonomy of cancer patients on deciding whether they want to be informed about interventional studies for fatigue. <i>Palliative Medicine</i> , 2016, 30, 897-898.	1.3	2
142	A study of motivations and expectations of patients seen in phase 1 oncology clinics. <i>Cancer</i> , 2016, 122, 3501-3508.	2.0	24
143	Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. <i>Acta Oncologica</i> , 2016, 55, 1510-1512.	0.8	10
144	How did partners experience cancer patients' participation in a phase I study? An observational study after a patient's death. <i>Palliative and Supportive Care</i> , 2016, 14, 241-249.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 2745-2752.	0.7	36
146	Olaratumab in soft-tissue sarcomas. <i>Lancet, The</i> , 2016, 388, 442-444.	6.3	11
147	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. <i>Oncolimmunology</i> , 2016, 5, e1191732.	2.1	17
148	Fatigue and its associated psychosocial factors in cancer patients on active palliative treatment measured over time. <i>Supportive Care in Cancer</i> , 2016, 24, 1349-1355.	1.0	20
149	Phase 2 Study of Lutetium 177 <sup>â€</sup> Labeled Anti <sup>â€</sup> Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 767-770.	0.9	57
150	Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer <sup>â€</sup> Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. <i>European Journal of Cancer</i> , 2016, 58, 62-72.	1.3	114
151	Patients <sup>â€™</sup> Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist <sup>â€™</sup> s Awareness of These Preferences. <i>Journal of Cancer Education</i> , 2016, 31, 443-448.	0.6	17
152	Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma. <i>Head and Neck</i> , 2016, 38, E559-65.	0.9	19
153	Clinical characteristics and treatment outcome in a large multicenter observational cohort of pdgfra exon 18 mutated gastrointestinal stromal tumor (GIST) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11011-11011.	0.8	1
154	Salivary duct carcinoma: Clinical outcomes and prognostic factors in 157 patients and results of androgen deprivation therapy in recurrent disease (n=31) <sup>â€™</sup> Study of the Dutch head and neck society (DHNS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6016-6016.	0.8	8
155	Prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6079-6079.	0.8	1
156	First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. <i>Oncotarget</i> , 2016, 7, 80046-80058.	0.8	90
157	Prognostic factors for overall survival of patients with head and neck soft tissue sarcoma based on 25 years data from the Netherlands Cancer registry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6050-6050.	0.8	0
158	Health <sup>â€</sup> related quality <sup>â€</sup> of <sup>â€</sup> life results from PALETTE: A randomized, double <sup>â€</sup> blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy <sup>â€™</sup> a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). <i>Cancer</i> , 2015, 121, 2933-2941.	2.0	72
159	Synovial sarcoma diagnosis and management in the era of targeted therapies. <i>Current Opinion in Oncology</i> , 2015, 27, 316-322.	1.1	25
160	Exploring the Routine Administration of Decision Aids for Palliative Chemotherapy to Patients by Nurses. <i>Cancer Nursing</i> , 2015, 38, 270-278.	0.7	3
161	Next generation sequencing in synovial sarcoma reveals novel gene mutations. <i>Oncotarget</i> , 2015, 6, 34680-34690.	0.8	45
162	Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0117745.	1.1	32

#	ARTICLE	IF	CITATIONS
163	Expected survival with and without secondâ€line palliative chemotherapy: who wants to know?. Health Expectations, 2015, 18, 2903-2914.	1.1	7
164	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. Journal of Clinical Oncology, 2015, 33, 4276-4283.	0.8	148
165	FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment. Nuclear Medicine and Molecular Imaging, 2015, 49, 237-240.	0.6	6
166	Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle. Targeted Oncology, 2015, 10, 439-443.	1.7	5
167	BREATH: Web-Based Self-Management for Psychological Adjustment After Primary Breast Cancerâ€™Results of a Multicenter Randomized Controlled Trial. Journal of Clinical Oncology, 2015, 33, 2763-2771.	0.8	153
168	Redefining the standard of care in metastatic leiomyosarcoma. Lancet Oncology, The, 2015, 16, 360-362.	5.1	5
169	Promising management of pazopanib-induced liver toxicity. Acta OncolÃ³gica, 2015, 54, 1064-1066.	0.8	8
170	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Physics, 2015, 2, 5.	1.3	10
171	A prospective analysis on fatigue and experienced burden in informal caregivers of cancer patients during cancer treatment in the palliative phase. Acta OncolÃ³gica, 2015, 54, 500-506.	0.8	30
172	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. Clinical Cancer Research, 2015, 21, 3436-3441.	3.2	34
173	Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 848-857.	3.3	25
174	Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles?. Acta OncolÃ³gica, 2015, 54, 1202-1208.	0.8	29
175	Age as an independent prognostic factor for survival of localised synovial sarcoma patients. British Journal of Cancer, 2015, 113, 1602-1606.	2.9	85
176	Pharmacogenetic markers for efficacy and toxicity of chemotherapy in osteosarcoma patients.. Journal of Clinical Oncology, 2015, 33, 10054-10054.	0.8	0
177	A biopsy-guided analysis of diarrhea in patients treated with tyrosine kinase inhibitors of the vascular endothelial growth factor receptor.. Journal of Clinical Oncology, 2015, 33, e15596-e15596.	0.8	0
178	Association of pharmacogenetic variants with progressive disease in osteosarcoma patients.. Journal of Clinical Oncology, 2015, 33, 10057-10057.	0.8	0
179	Association of hematological toxicity (tox) and outcome to doxorubicin (DOX) in advanced soft tissue sarcoma (STS): A retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database.. Journal of Clinical Oncology, 2015, 33, 10544-10544.	0.8	0
180	Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. Anticancer Research, 2015, 35, 5601-6.	0.5	2

#	ARTICLE	IF	CITATIONS
181	Feasibility and Impact of a Physical Exercise Program in Patients with Advanced Cancer: A Pilot Study. <i>Journal of Palliative Medicine</i> , 2014, 17, 1091-1098.	0.6	40
182	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. <i>Molecular Pharmaceutics</i> , 2014, 11, 4249-4257.	2.3	8
183	Exploring the contribution of psychosocial factors to fatigue in patients with advanced incurable cancer. <i>Psycho-Oncology</i> , 2014, 23, 773-779.	1.0	24
184	Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. <i>International Journal of Cancer</i> , 2014, 135, 2770-2782.	2.3	20
185	Solitary fibrous tumor – clinicopathologic, immunohistochemical and molecular analysis of 28 cases. <i>Diagnostic Pathology</i> , 2014, 9, 224.	0.9	107
186	Severe Fatigue During the Palliative Treatment Phase of Cancer. <i>Cancer Nursing</i> , 2014, 37, 139-145.	0.7	19
187	Epigenetic targeting in pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 656-664.	3.4	36
188	Theranostic applications of antibodies in oncology. <i>Molecular Oncology</i> , 2014, 8, 799-812.	2.1	53
189	Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. <i>Targeted Oncology</i> , 2014, 9, 339-347.	1.7	28
190	Dynamics of IGF-1R Expression During Endocrine Breast Cancer Treatment. <i>Molecular Imaging and Biology</i> , 2014, 16, 529-37.	1.3	4
191	Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 266-276.	3.3	31
192	Radionuclide imaging of drug delivery for patient selection in targeted therapy. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 175-185.	2.4	7
193	Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. <i>Clinical Sarcoma Research</i> , 2014, 4, 7.	2.3	47
194	Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 457-463.	1.1	15
195	Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1593-602.	3.3	33
196	Anti-angiogenic therapy, a new player in the field of sarcoma treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 172-185.	2.0	28
197	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 415-423.	5.1	864
198	Association of genetic variants involved in drug metabolism and transport with efficacy and toxicity of chemotherapeutic treatment in osteosarcoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10038-10038.	0.8	1

#	ARTICLE	IF	CITATIONS
199	Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2014, 32, 10579-10579.	0.8	2
200	The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma. Oncotarget, 2014, 5, 12753-12768.	0.8	46
201	Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine. Current Pharmaceutical Design, 2014, 20, 2293-2307.	0.9	3
202	Degree of nephrotoxicity after intermediate or high-dose cisplatin-based chemoradiotherapy (CRT) in patients with locally advanced head and neck cancer (LAHNC).. Journal of Clinical Oncology, 2014, 32, 6056-6056.	0.8	0
203	Quality of life of patients with locally advanced head and neck cancer (LAHNC) treated with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing chemoradiotherapy (CRT).. Journal of Clinical Oncology, 2014, 32, 6053-6053.	0.8	0
204	Survival of adolescents and young adults (AYAs) with skeletal Ewing sarcoma: A Dutch population-based study.. Journal of Clinical Oncology, 2014, 32, 10530-10530.	0.8	0
205	Osteosarcoma of the head and neck (OHN): A multicenter case series of 79 adult patients in the Netherlands.. Journal of Clinical Oncology, 2014, 32, 10542-10542.	0.8	0
206	Surgical management of rectal gastrointestinal stromal tumors. Journal of Surgical Oncology, 2013, 107, 320-323.	0.8	57
207	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSC Experience. Annals of Surgical Oncology, 2013, 20, 2937-2943.	0.7	190
208	FELD better not thinking of metastases only when liver lesions appear after bleomycin-based treatment for non-seminoma testis from metastases. BMC Cancer, 2013, 13, 491.	1.1	1
209	Pheochromocytoma and Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis Type I. American Journal of Medicine, 2013, 126, 174-180.	0.6	35
210	Pigmented villonodular synovitis: current concepts about diagnosis and management. Future Oncology, 2013, 9, 1515-1531.	1.1	39
211	Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: A rational choice. European Journal of Cancer, 2013, 49, 3462-3470.	1.3	35
212	The strength of small: Improved targeting of Insulin-like Growth Factor-1 Receptor (IGF-1R) with F(ab $\epsilon$ ) <sub>2</sub> -R1507 fragments in Ewing sarcomas. European Journal of Cancer, 2013, 49, 2851-2858.	1.3	10
213	Expression and clinical relevance of MET and ALK in Ewing sarcomas. International Journal of Cancer, 2013, 133, 427-436.	2.3	48
214	Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects. Head and Neck, 2013, 35, E246-50.	0.9	10
215	Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans. Hypertension, 2013, 61, 1060-1065.	1.3	50
216	Bevacizumab reduces tumor targeting of anti-epidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. International Journal of Cancer, 2013, 133, 307-314.	2.3	49

#	ARTICLE	IF	CITATIONS
217	IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization. <i>Future Oncology</i> , 2013, 9, 1733-1740.	1.1	7
218	Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10500-10500.	0.8	32
219	Induction chemotherapy (IC) with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing concomitant chemoradiotherapy (CRT) in fit patients with locally advanced head and neck cancer (LAHNC): The CONDOR studyâ€”A study of the Dutch Head and Neck Society.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6057-6057.	0.8	3
220	Long-term responders and survivors on pazopanib for soft tissue sarcomas (STS): Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10553-10553.	0.8	0
221	A randomized trial of a nurse-led decision aid to inform patients with advanced cancer about palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20583-e20583.	0.8	0
222	Fear of disease progression in patients with gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2013, 31, 10549-10549.	0.8	0
223	Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications. <i>Journal of Clinical Oncology</i> , 2012, 30, 308-315.	0.8	108
224	A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients. <i>Clinical Cancer Research</i> , 2012, 18, 5780-5787.	3.2	96
225	Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 146-153.	2.8	66
226	Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1926-1932.	2.8	12
227	18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors. <i>World Journal of Nuclear Medicine</i> , 2012, 11, 65-69.	0.3	7
228	Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?. <i>World Journal of Surgical Oncology</i> , 2012, 10, 111.	0.8	30
229	Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway. <i>Anti-Cancer Drugs</i> , 2012, 23, 149-154.	0.7	5
230	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2012, 379, 1879-1886.	6.3	1,752
231	Pazopanib for metastatic soft-tissue sarcoma â€” Authors' reply. <i>Lancet</i> , The, 2012, 380, 801.	6.3	4
232	Optimization of IGF-1R SPECT/CT Imaging Using <sup>111</sup> In-Labeled F(ab <sup>2</sup> ) and Fab Fragments of the Monoclonal Antibody R1507. <i>Molecular Pharmaceutics</i> , 2012, 9, 2314-2321.	2.3	35
233	IGF-1R <sup>2</sup> -Insulin-Like Growth Factor <sup>1R</sup> Signaling Is an Autocrine Survival Pathway in Gastrointestinal Stromal Tumors. <i>American Journal of Pathology</i> , 2012, 181, 303-312.	1.9	14
234	<sup>18</sup> F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1904-1910.	2.8	44

#	ARTICLE	IF	CITATIONS
235	Cancer in adolescents and young adults (15–29 years): A population-based study in the Netherlands 1989–2009. <i>Acta Oncologica</i> , 2012, 51, 922-933.	0.8	82
236	New Systemic Therapy Options for Advanced Sarcomas. <i>Current Treatment Options in Oncology</i> , 2012, 13, 306-317.	1.3	17
237	Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 259-279.	2.0	31
238	Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. <i>EJNMMI Research</i> , 2012, 2, 5.	1.1	22
239	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012, 118, 1649-1655.	2.0	222
240	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10009-10009.	0.8	4
241	Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2593-2593.	0.8	20
242	A phase Ib study of the combination of temsirolimus (T) and pegylated liposomal doxorubicin (PLD) in advanced or recurrent breast, endometrial, and ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5061-5061.	0.8	1
243	Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10067-10067.	0.8	0
244	Patient information desire in actual decision making for advanced cancer treatment: Do doctors know their patients?. <i>Journal of Clinical Oncology</i> , 2012, 30, 9036-9036.	0.8	0
245	The effect of bevacizumab on targeting of anti-epidermal growth factor receptor and anti-insulin-like growth factor 1 receptor antibodies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3035-3035.	0.8	0
246	PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 233-242.	12.5	75
247	Age as prognostic factor in patients with osteosarcoma. <i>Bone</i> , 2011, 49, 1173-1177.	1.4	33
248	Quality of pathology reports for advanced ovarian cancer: Are we missing essential information?. <i>European Journal of Cancer</i> , 2011, 47, 57-64.	1.3	34
249	Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. <i>Lancet Oncology</i> , The, 2011, 12, 1053-1061.	5.1	66
250	Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 725-736.	1.1	53
251	Assessing the information desire of patients with advanced cancer by providing information with a decision aid, which is evaluated in a randomized trial: a study protocol. <i>BMC Medical Informatics and Decision Making</i> , 2011, 11, 9.	1.5	18
252	Family-oriented multilevel study on the psychological functioning of adolescent children having a mother with cancer. <i>Psycho-Oncology</i> , 2011, 20, 730-737.	1.0	60

#	ARTICLE	IF	CITATIONS
253	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. <i>International Journal of Cancer</i> , 2011, 129, 507-512.	2.3	120
254	Clinical applications of positron emission tomography in sarcoma management. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 195-204.	1.1	22
255	When Hope Is All There Is Left. <i>Oncologist</i> , 2011, 16, 914-916.	1.9	5
256	Nuclear Medicine Imaging of Infection in Cancer Patients (With Emphasis on FDG-PET). <i>Oncologist</i> , 2011, 16, 980-991.	1.9	15
257	Adolescents' Emotional Reactions to Parental Cancer: Effect on Emotional and Behavioral Problems. <i>Journal of Pediatric Psychology</i> , 2011, 36, 346-359.	1.1	36
258	Androgen Receptor-Positive Salivary Duct Carcinoma: A Disease Entity With Promising New Treatment Options. <i>Journal of Clinical Oncology</i> , 2011, 29, e473-e476.	0.8	164
259	Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507. <i>Clinical Cancer Research</i> , 2011, 17, 7693-7703.	3.2	39
260	Malignant Transformation in an Area With Elevated F-18 FDG Uptake Within a Low Metabolic Benign Neurofibroma. <i>Clinical Nuclear Medicine</i> , 2010, 35, 271-272.	0.7	0
261	Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. <i>Anti-Cancer Drugs</i> , 2010, 21, 749-758.	0.7	38
262	Stress response symptoms in adolescents during the first year after a parent's cancer diagnosis. <i>Supportive Care in Cancer</i> , 2010, 18, 1421-1428.	1.0	30
263	Temsirolimus for metastatic desmoplastic small round cell tumor. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1431-1432.	0.8	36
264	Starting an Adolescent and Young Adult Program: Some Success Stories and Some Obstacles to Overcome. <i>Journal of Clinical Oncology</i> , 2010, 28, 4850-4857.	0.8	199
265	Pretargeted Immuno-Positron Emission Tomography Imaging of Carcinoembryonic Antigen-Expressing Tumors with a Bispecific Antibody and a <sup>68</sup> Ga- and <sup>18</sup> F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1019-1027.	1.9	85
266	Pretargeted <sup>177</sup> Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1780-1787.	2.8	49
267	ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1565-1572.	2.8	84
268	<sup>111</sup> In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1707-1715.	2.8	47
269	Imaging of HIV-Associated Kaposi Sarcoma; F-18-FDG-PET/CT and In-111-Bevacizumabscintigraphy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 444-446.	0.9	15
270	Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. <i>Acta Oncologica</i> , 2010, 49, 113-116.	0.8	13



#	ARTICLE	IF	CITATIONS
271	Molecular imaging of solid tumors: exploiting the potential. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 609-611.	12.5	7
272	The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. <i>Acta Oncologica</i> , 2009, 48, 927-931.	0.8	54
273	Dying at the Right Time: A Modern Dilemma. <i>Oncologist</i> , 2009, 14, 642-643.	1.9	3
274	Parent-child communication patterns during the first year after a parent's cancer diagnosis. <i>Cancer</i> , 2009, 115, 4227-4237.	2.0	28
275	Metastatic potential of an aneurysmal bone cyst. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 455, 455-459.	1.4	40
276	The insulin-like growth factor system and sarcomas. <i>Journal of Pathology</i> , 2009, 217, 469-482.	2.1	125
277	Monitoring and Predicting Response to Therapy with <sup>18</sup> F-FDG PET in Colorectal Cancer: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2009, 50, 43S-54S.	2.8	197
278	Time to target evaluation criteria of targeted therapies. <i>Nuclear Medicine Communications</i> , 2009, 30, 487-489.	0.5	1
279	The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 189-197.	1.1	97
280	Quality of life of parents with children living at home: when one parent has cancer. <i>Supportive Care in Cancer</i> , 2008, 16, 133-141.	1.0	41
281	Measurement of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples. <i>Clinical Biochemistry</i> , 2008, 41, 636-639.	0.8	11
282	Spinal Extradural Metastasis: Review of Current Treatment Options. <i>Ca-A Cancer Journal for Clinicians</i> , 2008, 58, 245-259.	157.7	185
283	Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 1239-1246.	0.8	181
284	Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas. <i>Oncologist</i> , 2008, 13, 1193-1200.	1.9	22
285	Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. <i>Endocrine-Related Cancer</i> , 2007, 14, 979-993.	1.6	187
286	Serum HER2 levels are increased in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 173-177.	2.9	51
287	Emotional and behavioral problems in children of parents recently diagnosed with cancer: A longitudinal study. <i>Acta Oncologica</i> , 2007, 46, 67-76.	0.8	42
288	The insulin-like growth factor 1 receptor in cancer: Old focus, new future. <i>European Journal of Cancer</i> , 2007, 43, 1895-1904.	1.3	155

#	ARTICLE	IF	CITATIONS
289	Isolated Limb Perfusion with Tumor Necrosis Factor Alpha and Melphalan for Locally Advanced Soft Tissue Sarcoma: Three Time Periods at Risk for Amputation. <i>Annals of Surgical Oncology</i> , 2007, 14, 1499-1506.	0.7	40
290	Temperament as a predictor of internalising and externalising problems in adolescent children of parents diagnosed with cancer. <i>Supportive Care in Cancer</i> , 2007, 15, 395-403.	1.0	13
291	The Prognostic Effect of the Number of Histologically Examined Axillary Lymph Nodes in Breast Cancer: Stage Migration or Age Association?. <i>Annals of Surgical Oncology</i> , 2006, 13, 465-474.	0.7	39
292	TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2006, 78, 161-171.	1.4	54
293	Radiotherapy plus concomitant and adjuvant temozolomide for leptomeningeal pilomyxoid astrocytoma: a case study. <i>Journal of Neuro-Oncology</i> , 2006, 80, 107-108.	1.4	23
294	The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient. <i>International Journal of Clinical Oncology</i> , 2006, 11, 478-481.	1.0	32
295	Parental cancer. <i>Cancer</i> , 2006, 106, 1178-1187.	2.0	61
296	Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. <i>Acta Oncologica</i> , 2006, 45, 175-183.	0.8	19
297	Indium-111 <sup>67</sup> Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2 <sup>+</sup> Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2276-2282.	0.8	270
298	Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2005, 99, 196-201.	0.7	29
299	Imatinib induces hypothyroidism in patients receiving levothyroxine. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 433-438.	2.3	132
300	The dilemma of the strive for apoptosis in oncology: mind the heart. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 101-113.	2.0	10
301	Radiation-Induced Sarcoma: A Challenge for the Surgeon. <i>Annals of Surgical Oncology</i> , 2005, 12, 237-245.	0.7	59
302	Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. <i>Tropical Medicine and International Health</i> , 2005, 10, 1251-1257.	1.0	50
303	New positron emission tomography tracer [11 C]carvedilol reveals P-glycoprotein modulation kinetics. <i>British Journal of Pharmacology</i> , 2005, 145, 1045-1051.	2.7	46
304	Colorectal cancer and the CHEK2 1100delC mutation. <i>Genes Chromosomes and Cancer</i> , 2005, 43, 377-382.	1.5	27
305	The Human Leukocyte Antigen Region and Colorectal Cancer Risk. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 303-306.	0.7	7
306	Emotional and behavioural functioning of children of a parent diagnosed with cancer: a cross-informant perspective. <i>Psycho-Oncology</i> , 2005, 14, 746-758.	1.0	127

#	ARTICLE	IF	CITATIONS
307	Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 9130-9137.	0.8	182
308	Non-islet cell tumour hypoglycaemia in a patient with a gastrointestinal stromal tumour. <i>Acta Oncologica</i> , 2005, 44, 764-766.	0.8	19
309	Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 8296-8304.	0.8	86
310	Feasibility of Withholding Antibiotics in Selected Febrile Neutropenic Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 7437-7444.	0.8	79
311	Risk Factors for Buruli Ulcer Disease ( <i>Mycobacterium ulcerans</i> Infection): Results from a Case-Control Study in Ghana. <i>Clinical Infectious Diseases</i> , 2005, 40, 1445-1453.	2.9	138
312	Stress response symptoms in adolescent and young adult children of parents diagnosed with cancer. <i>European Journal of Cancer</i> , 2005, 41, 288-295.	1.3	92
313	No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors. <i>European Journal of Cancer</i> , 2005, 41, 1819-1823.	1.3	13
314	RELIABILITY AND VALIDITY OF THE BURULI ULCER FUNCTIONAL LIMITATION SCORE QUESTIONNAIRE. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 72, 449-452.	0.6	22
315	Immunoglobulin M Antibody Responses to <i>Mycobacterium ulcerans</i> Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. <i>Vaccine Journal</i> , 2004, 11, 387-391.	2.6	21
316	No association between two MLH3 variants (S845G and P844L) and colorectal cancer risk. <i>Cancer Genetics and Cytogenetics</i> , 2004, 152, 70-71.	1.0	15
317	Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 581-590.	1.2	7
318	In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 131-138.	1.1	58
319	Variability in axillary lymph node dissection for breast cancer. <i>Journal of Surgical Oncology</i> , 2004, 87, 4-12.	0.8	56
320	The impact of parental cancer on children and the family: a review of the literature. <i>Cancer Treatment Reviews</i> , 2004, 30, 683-694.	3.4	293
321	Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. <i>Nuclear Medicine Communications</i> , 2004, 25, 433-438.	0.5	118
322	DEVELOPMENT OF A QUESTIONNAIRE ASSESSING BURULI ULCER-INDUCED FUNCTIONAL LIMITATION. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 70, 318-322.	0.6	20
323	BURULI ULCER AND SCHISTOSOMIASIS: NO ASSOCIATION FOUND. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 71, 318-321.	0.6	13
324	Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients. <i>Intensive Care Medicine</i> , 2003, 29, 2157-2161.	3.9	42

#	ARTICLE	IF	CITATIONS
325	Multidrug resistance proteins in rhabdomyosarcomas. <i>Cancer</i> , 2003, 97, 1999-2005.	2.0	39
326	Assessment of functional limitations caused by <i>Mycobacterium ulcerans</i> infection: towards a Buruli Ulcer Functional Limitation Score. <i>Tropical Medicine and International Health</i> , 2003, 8, 90-96.	1.0	41
327	Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [ <sup>11</sup> C]verapamil measured with PET. <i>NeuroImage</i> , 2003, 20, 1775-1782.	2.1	80
328	Mycolactones and <i>Mycobacterium ulcerans</i> disease. <i>Lancet, The</i> , 2003, 362, 1062-1064.	6.3	78
329	The HLA class III subregion is responsible for an increased breast cancer risk. <i>Human Molecular Genetics</i> , 2003, 12, 2311-2319.	1.4	37
330	A Sarcoid-like Reaction in a Patient with Hemangiopericytoma Mediastinal lymphadenopathy resulting in Confusion about Therapy. <i>Acta Oncologica</i> , 2003, 42, 790-791.	0.8	0
331	Psychosocial Consequences for Children of a Parent With Cancer. <i>Cancer Nursing</i> , 2003, 26, 195-202.	0.7	77
332	Analysis of an IS 2404 -Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic. <i>Journal of Clinical Microbiology</i> , 2003, 41, 794-797.	1.8	38
333	Histopathologic Features of <i>Mycobacterium ulcerans</i> Infection. <i>Emerging Infectious Diseases</i> , 2003, 9, 651-656.	2.0	134
334	The Relation Between Histological, Tumor-Biological and Clinical Parameters in Deep and Superficial Leiomyosarcoma and Leiomyoma. <i>Sarcoma</i> , 2002, 6, 105-110.	0.7	21
335	The African challenge. <i>Lancet, The</i> , 2002, 359, 1527-1528.	6.3	1
336	An oncological view on the blood-testis barrier. <i>Lancet Oncology, The</i> , 2002, 3, 357-363.	5.1	158
337	Testicular carcinoma and HLA Class II genes. <i>Cancer</i> , 2002, 95, 1857-1863.	2.0	11
338	Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. <i>Cancer and Metastasis Reviews</i> , 2002, 21, 167-183.	2.7	42
339	Beliefs and attitudes toward Buruli ulcer in Ghana.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 67, 207-213.	0.6	131
340	Syndrome X in testicularcancer survivors. <i>Lancet, The</i> , 2001, 357, 228-229.	6.3	14
341	Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor- $\alpha$ and melphalan. <i>Cancer</i> , 2001, 91, 1940-1948.	2.0	33
342	Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. , 2001, 91, 1304.		2

#	ARTICLE	IF	CITATIONS
343	A New Conservative Approach to Extravasation of Anthracyclines with Dimethylsulfoxide and Dexrazoxane. <i>Acta Oncologica</i> , 2001, 40, 541-542.	0.8	37
344	Routine bone scintigraphy in primary staging of soft tissue sarcoma. <i>Cancer</i> , 2000, 89, 1726-1731.	2.0	33
345	Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins. <i>Journal of Clinical Oncology</i> , 2000, 18, 3211-3220.	0.8	222
346	Effects of peripheral stem-cell or bone-marrow reinfusion on peripheral serotonin metabolism. <i>Lancet, The</i> , 1999, 353, 293-294.	6.3	5
347	<i>Mycobacterium ulcerans</i> infection. <i>Lancet, The</i> , 1999, 354, 1013-1018.	6.3	271
348	Decision-making process in patients before entering phase III cancer clinical trials: A pilot study. <i>Cancer Nursing</i> , 1999, 22, 119-125.	0.7	22
349	5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. <i>Cancer</i> , 1995, 75, 1072-1076.	2.0	6
350	In vitro and in vivo studies on the action of BW502U83, an arylmethylaminopropanediol. <i>Anti-Cancer Drugs</i> , 1995, 6, 34-39.	0.7	2
351	Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 477-482.	1.1	5
352	Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms <i>In Vitro</i> . <i>International Journal of Cancer</i> , 1993, 55, 330-337.	2.3	10
353	Teniposide for meningeal carcinomatosis of small cell lung cancer. <i>Lung Cancer</i> , 1993, 10, 247-249.	0.9	5
354	<i>Mycobacterium ulcerans</i> infection in Ashanti region, Ghana. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1989, 83, 410-413.	0.7	71
355	Clinical trials in Desmoid-type Fibromatosis in children and (young) adults: A systematic review. <i>Pediatric Blood and Cancer</i> , 0, , .	0.8	0